Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA:688266)
China
· Delayed Price · Currency is CNY 91.39
-1.81 (-1.94%)
May 14, 2025, 2:45 PM CST
SHA:688266 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Net Income | -139.06 | -150.3 | -278.58 | -457.33 | -451 | -319.23 | Upgrade
|
| Depreciation & Amortization | 55.6 | 55.6 | 54.64 | 66.37 | 50.77 | 34.72 | Upgrade
|
| Other Amortization | 5.73 | 5.73 | 5.76 | 4.44 | 2.62 | 0.44 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.02 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | -3.92 | -3.92 | 0.28 | 0.11 | 0.01 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -2.94 | -2.94 | -14.68 | -6.58 | -12.8 | -12.28 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 0.64 | 1.4 | 3.28 | - | Upgrade
|
| Other Operating Activities | -125.31 | -18.79 | 8.77 | -15.57 | -4.53 | 9.71 | Upgrade
|
| Change in Accounts Receivable | -58.17 | -58.17 | -38.35 | -17.41 | -84.19 | -20.87 | Upgrade
|
| Change in Inventory | -72.01 | -72.01 | -11.87 | -47.07 | -28.77 | -16.71 | Upgrade
|
| Change in Accounts Payable | 285.27 | 285.27 | 78.49 | 67.14 | 38.99 | -46.68 | Upgrade
|
| Change in Other Net Operating Assets | 1.62 | 1.62 | -34.11 | 37.07 | 34.62 | 31.12 | Upgrade
|
| Operating Cash Flow | -57.07 | 38.2 | -232.75 | -370.34 | -454.62 | -343.86 | Upgrade
|
| Capital Expenditures | -99.27 | -95.69 | -62.6 | -88.62 | -70.74 | -57.68 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0 | 0 | 0 | - | Upgrade
|
| Investment in Securities | -1,471 | -1,764 | 115 | -182.1 | 380.01 | -441.57 | Upgrade
|
| Other Investing Activities | 14.63 | 14.86 | 12.44 | 6.66 | 17.39 | - | Upgrade
|
| Investing Cash Flow | -1,556 | -1,845 | 64.84 | -264.06 | 326.66 | -499.25 | Upgrade
|
| Long-Term Debt Issued | - | 1,288 | 983.8 | 561 | 171.4 | 67.65 | Upgrade
|
| Long-Term Debt Repaid | - | -1,135 | -644.19 | -242.77 | -64.91 | -80 | Upgrade
|
| Net Debt Issued (Repaid) | 25.8 | 153.48 | 339.61 | 318.23 | 106.49 | -12.35 | Upgrade
|
| Issuance of Common Stock | 0.34 | 0.34 | 1,192 | - | - | 2,026 | Upgrade
|
| Common Dividends Paid | -24.64 | -24.56 | -21.17 | -11.22 | -4.14 | -1.11 | Upgrade
|
| Other Financing Activities | -179.23 | -180.57 | -1.45 | -24.23 | -8.36 | -113.1 | Upgrade
|
| Financing Cash Flow | -177.72 | -51.32 | 1,509 | 282.79 | 93.99 | 1,899 | Upgrade
|
| Foreign Exchange Rate Adjustments | -2.32 | -2.3 | 0.22 | 4.07 | -1.44 | -3.79 | Upgrade
|
| Net Cash Flow | -1,793 | -1,861 | 1,342 | -347.54 | -35.41 | 1,052 | Upgrade
|
| Free Cash Flow | -156.34 | -57.49 | -295.35 | -458.97 | -525.36 | -401.54 | Upgrade
|
| Free Cash Flow Margin | -26.39% | -10.79% | -76.43% | -151.82% | -275.98% | -1451.64% | Upgrade
|
| Free Cash Flow Per Share | -0.59 | -0.22 | -1.16 | -1.92 | -2.19 | -1.71 | Upgrade
|
| Cash Income Tax Paid | 46.04 | 51.24 | 15.67 | -17.55 | -30.33 | 7.96 | Upgrade
|
| Levered Free Cash Flow | -44.74 | -130.35 | -325.09 | -297.1 | -353.47 | -238.38 | Upgrade
|
| Unlevered Free Cash Flow | -44.74 | -130.35 | -310.99 | -289.58 | -350.71 | -237.7 | Upgrade
|
| Change in Net Working Capital | -101.22 | -21.09 | 26.28 | -27.46 | 51.79 | 8.04 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.